Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis
- 1 January 2004
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 10 (2) , 97-100
- https://doi.org/10.1007/s10156-004-0303-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Clinical Role of Protein Binding of QuinolonesClinical Pharmacokinetics, 2002
- Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone AntibacterialsClinical Pharmacokinetics, 2001
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to OutcomeClinical Pharmacokinetics, 1995
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Postexposure Prophylaxis against Experimental Inhalation AnthraxThe Journal of Infectious Diseases, 1993
- Serum Concentrations of Penicillin, Doxycycline, and Ciprofloxacin during Prolonged Therapy in Rhesus MonkeysThe Journal of Infectious Diseases, 1992
- Phase I Study of Levofloxacin, (S)-(-)-Ofloxacin.Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1992
- Pharmacokinetics of Sparfloxacin in Man.Drug Metabolism and Pharmacokinetics, 1991
- Antimicrobial Susceptibility of Bacillus AnthracisScandinavian Journal of Infectious Diseases, 1991
- Extravascular penetration of ciprofloxacin a reviewDiagnostic Microbiology and Infectious Disease, 1990